These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34169200)

  • 21. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
    Licht C; Greenbaum LA; Muus P; Babu S; Bedrosian CL; Cohen DJ; Delmas Y; Douglas K; Furman RR; Gaber OA; Goodship T; Herthelius M; Hourmant M; Legendre CM; Remuzzi G; Sheerin N; Trivelli A; Loirat C
    Kidney Int; 2015 May; 87(5):1061-73. PubMed ID: 25651368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.
    Wang Y; Johnston K; Popoff E; Myren KJ; Cheung A; Faria C; Tomazos I
    J Med Econ; 2020 Dec; 23(12):1503-1515. PubMed ID: 33001704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
    Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
    Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?
    Menne J
    Kidney Int; 2020 Jun; 97(6):1106-1108. PubMed ID: 32444092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome.
    Syed YY
    Drugs; 2021 Apr; 81(5):587-594. PubMed ID: 33738756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies.
    Nowicki M; Printza N
    J Comp Eff Res; 2024 Nov; 13(11):e240103. PubMed ID: 39387237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data.
    Tomazos I; Hatswell AJ; Cataland S; Chen P; Freemantle N; Lommele Å; Deighton K; Knowles E; Sheerin NS; Rondeau E
    Clin Nephrol; 2022 May; 97(5):261-272. PubMed ID: 34931610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S; Bhalla A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced?
    Sethi A; Moses R
    Cureus; 2021 Feb; 13(2):e13260. PubMed ID: 33717763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States.
    Wang Y; Al-Dakkak I; Garlo K; Ong ML; Tomazos I; Mahajerin A
    Kidney Med; 2023 Aug; 5(8):100683. PubMed ID: 37415624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
    Walle JV; Delmas Y; Ardissino G; Wang J; Kincaid JF; Haller H
    J Nephrol; 2017 Feb; 30(1):127-134. PubMed ID: 26995002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome.
    Shen YM
    Thromb J; 2016; 14(Suppl 1):19. PubMed ID: 27766045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review.
    Shahid K; Qayyum S
    Cureus; 2023 Sep; 15(9):e46185. PubMed ID: 37905269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.
    Avila Bernabeu AI; Cavero Escribano T; Cao Vilarino M
    Nephron; 2020; 144(11):537-549. PubMed ID: 32950988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.